Medexus Pharmaceuticals Reports Mixed Q1 2025 Results

Medexus Pharmaceuticals Inc (TSE:MDP) has released an update.

Medexus Pharmaceuticals Inc. reported a decline in revenue to $27.3 million in fiscal Q1 2025, a 13.6% decrease from the previous year, primarily due to reduced sales of Rasuvo and IXINITY. Despite the revenue drop, the company achieved a net income increase to $2.0 million and maintained a strong Adjusted EBITDA of $6.1 million. These results reflect the company’s continued cost management efforts and revenue from key products like Rupall.

For further insights into TSE:MDP stock, check out TipRanks’ Stock Analysis page.